Label-Free Kinetic Studies of Hemostasis-Related Biomarkers Including D-Dimer Using Autologous Serum Transfusion
Open Access
- 14 December 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (12), e0145012
- https://doi.org/10.1371/journal.pone.0145012
Abstract
The objective of this study was to evaluate the elimination kinetics of hemostasis-related biomarkers including the prothrombin activation fragment F1+2, thrombin-antithrombin complex (TAT), plasmin-α2-antiplasmin complex (PAP), and D-dimer in humans. Autologous serum was used as a biomarker source and infused into 15 healthy volunteers. Serum was prepared from whole blood in the presence of recombinant tissue-type plasminogen activator (final concentration 20 μg/mL) to induce plasmin generation required for PAP and D-dimer formation. Serum transfusions (50 mL/30 min) were well tolerated by all subjects. Endogenous thrombin formation was not induced by serum infusions as measured using a highly sensitive oligonucleotide-based enzyme capture assay. Median peak levels (x-fold increase over baseline) of F1+2, TAT, PAP, and D-dimer of 3.7 nmol/L (28.9), 393 ng/mL (189.6), 3,829 ng/mL (7.0), and 13.4 mg/L (34.2) were achieved at the end of serum infusions. During a 48 h lasting follow-up period all biomarkers showed elimination kinetics of a two-compartment model. Median (interquartile range) terminal half-lives were 1.9 (1.3–3.6) h for F1+2, 0.7 (0.7–2.6) h for TAT, and 10.8 (8.8–11.4) h for PAP. With 15.8 (13.1–23.1) h the D-dimer half-life was about twice as long as previously estimated from radiolabeling studies in animals and small numbers of human subjects. The serum approach presented here allows label-free and simultaneous analysis of the elimination kinetics of various hemostasis-related biomarkers. Based on these data changes in biomarker levels could more precisely used to estimate the activity level of the hemostatic system.This publication has 57 references indexed in Scilit:
- Thrombin inhibition profiles in healthy individuals and thrombophilic patientsThrombosis and Haemostasis, 2012
- Prognostic Value of Plasma Fibrinolysis Activation Markers in Cardiovascular DiseaseJournal of the American College of Cardiology, 2010
- Elevated Levels of Prothrombin Fragment 1 + 2 Indicate High Risk of ThrombosisClinical and Applied Thrombosis/hemostasis, 2008
- Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteersThrombosis and Haemostasis, 2007
- Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIIIHaemophilia, 2006
- Achieving and maintaining quality in the laboratoryHaemophilia, 2006
- A reunification of the US (“NIH”) and International Unit into a single standard for ThrombinThrombosis and Haemostasis, 2005
- Reaction of human α2‐antiplasmin and plasmin Stopped‐flow fluorescence kineticsFEBS Letters, 1996
- Nomograms for the prediction of patient's plasma volume in plasma exchange therapy from height, weight, and hematocritJournal of Clinical Apheresis, 1987
- STUDIES IN INTRAVASCULAR COAGULATION. III. THE PATHOGENESIS OF SERUM-INDUCED VENOUS THROMBOSIS 12JCI Insight, 1955